PMID: 98 SpadaC.TreitingerA.ReisM.MasokawaI
2021 NEJM) randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg weekly or placebo for 68 weeks

How it works: Activates GLP-1 receptors in the body Year FDA approved (for weight loss): 2014 How taken: Once-a-day injection Average weight loss: 8% of body weight Common side effects: Nausea, vomiting, diarrhea, constipation, increased heart rate, dizziness, mood changes, fatigue, low blood glucose How it works: Activates GLP-1 receptors in the body Year FDA approved (for weight loss): 2021 How taken: Once-a-week injection or daily as a pill Average weight loss: 15% of body weight Common side effects: Nausea, vomiting, diarrhea, constipation, abdominal (belly) pain, headache, heartburn or reflux, dizziness, mood changes, fatigue, low blood glucose How it works: Activates GLP-1 and GIP receptors in the body Year FDA approved (for weight loss): 2022 How taken: Once-a-week injection Average weight loss: 20% of body weight Common side effects: Nausea, vomiting, diarrhea, constipation, abdominal (belly) pain, heartburn or reflux, dizziness, mood changes, fatigue, low blood glucose, redness at injection site, allergic reactions How it works: Activates GLP-1 receptors in the body Year FDA approved (for weight loss): 2026 How taken: Daily as a pill Average weight loss: 11% of body weight Common side effects: Nausea, vomiting, diarrhea, constipation, abdominal (belly) pain, headache, heartburn or reflux, gas, hair loss, low blood glucose Weight-loss results can vary based on the type and dosage of GLP-1 drug used

Lost productivity associated with diabetes and diabetic complications also impose a substantial economic burden on society
Pyrimethamine continues to be used, particularly in sub-Saharan Africa, for intermittent preventive treatment during pregnancy, where it helps reduce the risk of low birth weight associated with malaria [810], but also for seasonal malaria chemoprevention among children [11]